Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QTX3046 in Advanced Solid Tumors With KRAS G12D Mutations
NCT06428500Phase 1Active, not recruiting
- Sponsor
- Quanta Therapeutics
- Start
- May 2024
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of QTX3046 in solid tumor (advanced stage) (4 arms), sponsored by Quanta Therapeutics. Primary endpoints: Number of participants with Treatment-emergent Adverse Events up to 2 years and Number of participants with Dose Limiting Toxicities up to 21 days. Started May 2024; status: active, not recruiting.
02
Drugs
QTX3046
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06428500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06428500.